Lumida
/MAZE
⌘K
Maze Therapeutics Inc

Maze Therapeutics Inc

MAZE
$24.60USD↓-0.89%-0.22 today

MARKET CAP

1.4B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$24 – $26

52W RANGE

$20
$54

AI Summary

Stalk
TrimMedium

In Stage 4 decline, MAZE retains a medium-term bearish bias driven by recent Support Failure and Bearish Pivot Point patterns, with price trading below declining EMAs. Price now rests at a multi-touch support zone, making short-term timing unclear. Selling into resistance around the 9- and 20-day EMAs on a failed bounce is preferred over immediate execution.

  • ↑36% mean UACR reduction in Horizon Trial exceeds 30% threshold
  • ↑MZE829 targets ~6 million US AMKD patients lacking approved therapy
  • ↓Q2 2026 EPS of –$0.76 missed the –$0.70 estimate, underscoring losses
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical-stage biopharmaceutical company specializing in precision medicines targeting kidney and metabolic diseases. The company utilizes human genetics to inform its drug discovery processes, positioning itself as a significant player in the treatment of APOL1-mediated kidney disease (AMKD) with compounds like MZE829. As it advances through critical clinical trials, including the Horizon Trial for MZE829, it is poised to address unmet medical needs within a rapidly evolving market.

Bull says

  • ↑36% mean UACR reduction in Horizon Trial exceeds 30% threshold
  • ↑MZE829 targets ~6 million US AMKD patients lacking approved therapy
  • ↑Hedge funds’ strong 13F ownership signals institutional confidence
  • ↑Management plans pivotal trial entry with proactive regulatory strategy
  • ↑Strong momentum and growth factors suggest upside if profitability improves
  • ↑Anticipated $20 M Shinogi milestone payment supports near-term funding

Bear says

  • ↓Q2 2026 EPS of –$0.76 missed the –$0.70 estimate, underscoring losses
  • ↓Deeply negative earnings yield and poor profitability hinder stability
  • ↓QS factor flags high leverage and weak balance-sheet quality
  • ↓High stock volatility deters risk-averse investors
  • ↓Emerging AMKD therapies heighten competitive pressure
  • ↓Potential adverse events could derail or delay MZE829’s progress

Investment themes with MAZE

Pharmaceuticals↓ -0.48%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 08-31-2026bullish

Transcript signals

Bull points

  • MZE829 demonstrated a favorable safety profile and was well tolerated across patients in the HORIZON study consistent with prior Phase I studies.
  • I'm very pleased to share with you today that we have exceeded the 30% bar with MZE829 demonstrating 36% mean reduction in UACR in broad AMKD.
  • In patients with FSGS, we showed a 61.8% mean reduction in UACR. The FSGS data we present from Horizon today reinforce MZE829's potentially best-in-class efficacy in AMKD and differentiation through its dual mechanism of action.
Read full transcript analysis ›